Coordination complexes of platinum as antitumor agents

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Platinum coordination compounds exhibit bacteriostatic and antitumor properties.
• The clinical use of cis-dichlorodiammineplatinum (II) has shown efficacy against various mouse tumors.
• Renal toxicity is a significant limitation of cis-dichlorodiammineplatinum (II), necessitating the development of alternatives.

Purpose of the Study:

• To discuss the synthesis, purification, and testing of platinum coordination compounds.
• To explore promising platinum-based drug candidates, including cis-dichlorobiscyclopentylamine-platinum (II) and platinum blues.
• To identify unresolved challenges in the field of platinum-based anticancer agents.

Main Methods:

• Review of synthesis and testing methodologies for platinum coordination compounds.
• Analysis of preclinical data on the efficacy and toxicity of platinum-based drugs.
• Identification of key structural modifications influencing biological activity.

Main Results:

• Cis-dichlorodiammineplatinum (II) is effective but limited by renal toxicity.
• Newer platinum compounds, such as cis-dichlorobiscyclopentylamine-platinum (II) and platinum blues, show potential.
• Ongoing research aims to overcome the therapeutic limitations of existing platinum drugs.

Conclusions:

• Platinum coordination compounds remain a vital area of cancer chemotherapy research.
• Development of platinum-based drugs with reduced toxicity and enhanced antitumor activity is crucial.
• Further investigation into novel platinum complexes and their mechanisms of action is warranted.